{"success":true,"data":{"pressRelease":{"id":"48436","rtpr_id":"nGNX4STT1Z","ticker":"TVGN","exchange":"NASDAQ","all_tickers":["TVGN","TVGNW"],"title":"Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue","author":"Globe Newswire","published_at":"2026-05-28T16:30:00.101Z","article_body":"WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen\n(https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==)\n(“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN\n(https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg))\ntoday announced continued progress across its strategic acquisition\ninitiatives intended to complement its existing business and support long-term\nfinancial self-sufficiency, which, if consummated, could realize approximately\n$100 million in combined annual revenue. These initiatives include the\nCompany’s previously announced evaluation of a contract research\norganization (“CRO”), along with additional strategic acquisition\nopportunities aligned with Tevogen’s broader healthcare platform.\n\nTevogen believes these and other strategic acquisition initiatives could\nsupport the Company’s evolution into a revenue-generating healthcare\nenterprise comprised of Tevogen Bio, its biotechnology arm; Tevogen.AI, its\ntechnology arm; and, subject to completion of proposed transactions, a\nhealthcare services arm that may include management services and contract\nresearch operations.\n\n“Capital discipline and preserving the integrity of our capital structure\nare core priorities for us,” said Ryan Saadi, MD, MPH, Founder and CEO of\nTevogen Bio. “Our strategic objective is to build a financially\nself-sufficient healthcare enterprise with the financial strength to support\noperations, advance growth initiatives, and create long-term value through\nrevenue generation. The acquisition opportunities we are evaluating represent\nan initial phase of that strategy, and any related capital allocation\ndecisions will continue to be guided by strategic fit, long-term value\ncreation, and disciplined stewardship of Tevogen’s capital structure.”\n\nThe proposed transactions remain subject to, among other things, completion of\ndue diligence, negotiation and execution of definitive documentation, required\napprovals, and satisfaction of customary closing conditions. There can be no\nassurance that any such transaction will be consummated.\n\nAbout Tevogen\n\nTevogen is a socially integrated healthcare enterprise built on the principles\nof affordability, efficiency, and scientific rigor. The company leverages\nartificial intelligence and precision T cell therapy platforms, a\npatient-first and cost-disciplined operating model, and engagements with\nglobal technology leaders to support the development of advanced, life-saving\ntherapies across multiple therapeutic areas and scalable solutions for the\nbroader healthcare system.\n\nTevogen Bio, the company’s lead initiative, has completed a proof-of-concept\nclinical trial demonstrating the potential of its single-HLA-restricted,\ngenetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans\nvirology, oncology, and neurology, with programs built on the company’s\nproprietary ExacTcell™ platform.\n\nTevogen.AI is designed to transform drug development by accelerating target\ndetection, helping reduce failure rates, and supporting optimized clinical\ntrial design through proprietary predictive technologies. The platform\nutilizes cloud and data services from leading technology providers, including\nMicrosoft and Databricks, to advance its long-term ambition to predict the\nproteome for any given protein–HLA combination, enabling rapid and\ncost-efficient therapeutic discovery.\n\nTevogen is exploring future strategic initiatives that may include domestic\ngenerics, biosimilars, medical devices, and innovative insurance solutions for\nhealthcare providers. Together, these programs reflect Tevogen’s mission to\nadvance sustainable innovation and broaden patient access through a faster,\nmore efficient, and more equitable healthcare model.\n\nForward Looking Statements\n\nThis press release contains certain forward-looking statements, including\nwithout limitation statements relating to: the potential transaction and the\npotential benefits of the transaction; Tevogen’s plans for its research and\nmanufacturing capabilities; expectations regarding future growth; expectations\nregarding the healthcare and biopharmaceutical industries; and Tevogen’s\ndevelopment of, the potential benefits of, and patient access to its product\ncandidates for the treatment of infectious diseases and cancer.\nForward-looking statements can sometimes be identified by words such as\n“may,” “could,” “would,” “expect,” “anticipate,”\n“possible,” “potential,” “goal,” “opportunity,” “project,”\n“believe,” “future,” and similar words and expressions or their\nopposites. These statements are based on management’s expectations,\nassumptions, estimates, projections and beliefs as of the date of this press\nrelease and are subject to a number of factors that involve known and unknown\nrisks, delays, uncertainties and other factors not under the company’s\ncontrol that may cause actual results, performance or achievements of the\ncompany to be materially different from the results, performance or other\nexpectations expressed or implied by these forward-looking statements.\n\nFactors that could cause actual results, performance, or achievements to\ndiffer from those expressed or implied by forward-looking statements include,\nbut are not limited to: risks inherent in diligence and negotiation of the\nproposed transaction; the risk that the transaction may not be consummated on\nfavorable terms or at all; the risk that the expected benefits of the\ntransaction may not be realized on a timely basis or at all; changes in the\nmarkets in which Tevogen competes, including with respect to its competitive\nlandscape, technology evolution, or regulatory changes; changes in domestic\nand global general economic conditions; the risk that Tevogen may not be able\nto execute its growth strategies or may experience difficulties in managing\nits growth and expanding operations; the risk that Tevogen may not be able to\ndevelop and maintain effective internal controls; the failure to achieve\nTevogen’s commercialization and development plans and identify and realize\nadditional opportunities, which may be affected by, among other things,\ncompetition, the ability of Tevogen to grow and manage growth economically and\nhire and retain key employees; the risk that Tevogen may fail to keep pace\nwith rapid technological developments to provide new and innovative products\nand services or make substantial investments in unsuccessful new products and\nservices; that Tevogen will need to raise additional capital to fully realize\nits business plans; risks related to the ability to develop, license or\nacquire new therapeutics; the risk of regulatory lawsuits or proceedings\nrelating to Tevogen’s business; uncertainties inherent in the execution,\ncost, and completion of preclinical studies and clinical trials; risks related\nto regulatory review, approval and commercial development; risks associated\nwith intellectual property protection; Tevogen’s limited operating history;\nand those factors discussed or incorporated by reference in Tevogen’s most\nrecent Annual Report on Form 10-K and subsequent filings with the SEC.\n\nYou should not place undue reliance on forward-looking statements, which speak\nonly as of the date they are made. Tevogen undertakes no obligation to update\nany forward-looking statements, except as required by applicable law.\n\nContacts\n\nTevogen Bio Communications\nT: 1 877 TEVOGEN, Ext 701 \nCommunications@Tevogen.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/679fef4d-f32f-46a2-9452-c31af5cf4597)\nTevogen Advances Strategic Acquisition Initiatives with Potential to Support\nApproximately $100 Million in Combined Annual Revenue \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31e6e8f1-0984-4686-a852-d665eba4e5ad/en)\nTevogen Advances Strategic Acquisition Initiatives with Potential to Support\nApproximately $100 Million in Combined Annual Revenue\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4STT1Z","title":"Tevogen Advances Strategic Acquisition Initiatives with Potential to Support Approximately $100 Million in Combined Annual Revenue","author":"Globe Newswire","ticker":"TVGN","created":"2026-05-28T16:30:00.101Z","tickers":["TVGN","TVGNW"],"exchange":"NASDAQ","article_body":"WARREN, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Tevogen\n(https://www.globenewswire.com/Tracker?data=EUcdivTuGvletcA08jAdFYmbip2qCrwA5b-gIoecUvUCkaSPXT7zk6IPCHYsP84OVLNTRsUiXTm4_1zlY9Rzzw==)\n(“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN\n(https://www.globenewswire.com/Tracker?data=4dIpR_vpvIwuP9gBnkY-EepARo1hOOySfkS2LU7XslZoS2NyrmvJLe9pEWs5pX7X09YJsEASBJghEUn6HC6i087BSZzSN7zDFOiV2p7rCPQoHIU8lpmwU3I4uLAoASpg))\ntoday announced continued progress across its strategic acquisition\ninitiatives intended to complement its existing business and support long-term\nfinancial self-sufficiency, which, if consummated, could realize approximately\n$100 million in combined annual revenue. These initiatives include the\nCompany’s previously announced evaluation of a contract research\norganization (“CRO”), along with additional strategic acquisition\nopportunities aligned with Tevogen’s broader healthcare platform.\n\nTevogen believes these and other strategic acquisition initiatives could\nsupport the Company’s evolution into a revenue-generating healthcare\nenterprise comprised of Tevogen Bio, its biotechnology arm; Tevogen.AI, its\ntechnology arm; and, subject to completion of proposed transactions, a\nhealthcare services arm that may include management services and contract\nresearch operations.\n\n“Capital discipline and preserving the integrity of our capital structure\nare core priorities for us,” said Ryan Saadi, MD, MPH, Founder and CEO of\nTevogen Bio. “Our strategic objective is to build a financially\nself-sufficient healthcare enterprise with the financial strength to support\noperations, advance growth initiatives, and create long-term value through\nrevenue generation. The acquisition opportunities we are evaluating represent\nan initial phase of that strategy, and any related capital allocation\ndecisions will continue to be guided by strategic fit, long-term value\ncreation, and disciplined stewardship of Tevogen’s capital structure.”\n\nThe proposed transactions remain subject to, among other things, completion of\ndue diligence, negotiation and execution of definitive documentation, required\napprovals, and satisfaction of customary closing conditions. There can be no\nassurance that any such transaction will be consummated.\n\nAbout Tevogen\n\nTevogen is a socially integrated healthcare enterprise built on the principles\nof affordability, efficiency, and scientific rigor. The company leverages\nartificial intelligence and precision T cell therapy platforms, a\npatient-first and cost-disciplined operating model, and engagements with\nglobal technology leaders to support the development of advanced, life-saving\ntherapies across multiple therapeutic areas and scalable solutions for the\nbroader healthcare system.\n\nTevogen Bio, the company’s lead initiative, has completed a proof-of-concept\nclinical trial demonstrating the potential of its single-HLA-restricted,\ngenetically unmodified allogeneic T cells. Tevogen Bio’s pipeline spans\nvirology, oncology, and neurology, with programs built on the company’s\nproprietary ExacTcell™ platform.\n\nTevogen.AI is designed to transform drug development by accelerating target\ndetection, helping reduce failure rates, and supporting optimized clinical\ntrial design through proprietary predictive technologies. The platform\nutilizes cloud and data services from leading technology providers, including\nMicrosoft and Databricks, to advance its long-term ambition to predict the\nproteome for any given protein–HLA combination, enabling rapid and\ncost-efficient therapeutic discovery.\n\nTevogen is exploring future strategic initiatives that may include domestic\ngenerics, biosimilars, medical devices, and innovative insurance solutions for\nhealthcare providers. Together, these programs reflect Tevogen’s mission to\nadvance sustainable innovation and broaden patient access through a faster,\nmore efficient, and more equitable healthcare model.\n\nForward Looking Statements\n\nThis press release contains certain forward-looking statements, including\nwithout limitation statements relating to: the potential transaction and the\npotential benefits of the transaction; Tevogen’s plans for its research and\nmanufacturing capabilities; expectations regarding future growth; expectations\nregarding the healthcare and biopharmaceutical industries; and Tevogen’s\ndevelopment of, the potential benefits of, and patient access to its product\ncandidates for the treatment of infectious diseases and cancer.\nForward-looking statements can sometimes be identified by words such as\n“may,” “could,” “would,” “expect,” “anticipate,”\n“possible,” “potential,” “goal,” “opportunity,” “project,”\n“believe,” “future,” and similar words and expressions or their\nopposites. These statements are based on management’s expectations,\nassumptions, estimates, projections and beliefs as of the date of this press\nrelease and are subject to a number of factors that involve known and unknown\nrisks, delays, uncertainties and other factors not under the company’s\ncontrol that may cause actual results, performance or achievements of the\ncompany to be materially different from the results, performance or other\nexpectations expressed or implied by these forward-looking statements.\n\nFactors that could cause actual results, performance, or achievements to\ndiffer from those expressed or implied by forward-looking statements include,\nbut are not limited to: risks inherent in diligence and negotiation of the\nproposed transaction; the risk that the transaction may not be consummated on\nfavorable terms or at all; the risk that the expected benefits of the\ntransaction may not be realized on a timely basis or at all; changes in the\nmarkets in which Tevogen competes, including with respect to its competitive\nlandscape, technology evolution, or regulatory changes; changes in domestic\nand global general economic conditions; the risk that Tevogen may not be able\nto execute its growth strategies or may experience difficulties in managing\nits growth and expanding operations; the risk that Tevogen may not be able to\ndevelop and maintain effective internal controls; the failure to achieve\nTevogen’s commercialization and development plans and identify and realize\nadditional opportunities, which may be affected by, among other things,\ncompetition, the ability of Tevogen to grow and manage growth economically and\nhire and retain key employees; the risk that Tevogen may fail to keep pace\nwith rapid technological developments to provide new and innovative products\nand services or make substantial investments in unsuccessful new products and\nservices; that Tevogen will need to raise additional capital to fully realize\nits business plans; risks related to the ability to develop, license or\nacquire new therapeutics; the risk of regulatory lawsuits or proceedings\nrelating to Tevogen’s business; uncertainties inherent in the execution,\ncost, and completion of preclinical studies and clinical trials; risks related\nto regulatory review, approval and commercial development; risks associated\nwith intellectual property protection; Tevogen’s limited operating history;\nand those factors discussed or incorporated by reference in Tevogen’s most\nrecent Annual Report on Form 10-K and subsequent filings with the SEC.\n\nYou should not place undue reliance on forward-looking statements, which speak\nonly as of the date they are made. Tevogen undertakes no obligation to update\nany forward-looking statements, except as required by applicable law.\n\nContacts\n\nTevogen Bio Communications\nT: 1 877 TEVOGEN, Ext 701 \nCommunications@Tevogen.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/679fef4d-f32f-46a2-9452-c31af5cf4597)\nTevogen Advances Strategic Acquisition Initiatives with Potential to Support\nApproximately $100 Million in Combined Annual Revenue \n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31e6e8f1-0984-4686-a852-d665eba4e5ad/en)\nTevogen Advances Strategic Acquisition Initiatives with Potential to Support\nApproximately $100 Million in Combined Annual Revenue\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-05-28T16:30:00.134099678Z","server_sent_at_ms":1779985800134},"received_at":"2026-05-28T16:30:00.269Z","source_url":null},"analysis":{"id":"37870","press_release_id":"48436","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["No definitive agreements signed; transactions subject to due diligence and closing conditions","Highly speculative revenue projections based on uncompleted deals","Company has limited operating history and may need to raise additional capital"],"eventType":"m_and_a","narrative":"Tevogen is advancing strategic acquisition initiatives, including the evaluation of a contract research organization (CRO), aimed at building a financially self-sufficient healthcare enterprise.\n\nIf consummated, these transactions could support approximately $100 million in combined annual revenue, diversifying the company beyond its current biotechnology and AI arms.\n\nThe company emphasized capital discipline, noting that any acquisitions will be guided by strategic fit and long-term value creation, though no definitive agreements have been executed.","sentiment":"bullish","agentHooks":{"shouldPost":true,"suggestedAngle":"Tevogen pivots to M&A strategy with potential $100M revenue upside, signaling shift toward financial self-sufficiency."},"keyFigures":{"customDimensions":{"potential_annual_revenue":"$100 million"}},"quotedText":"Our strategic objective is to build a financially self-sufficient healthcare enterprise with the financial strength to support operations, advance growth initiatives, and create long-term value through revenue generation.","namedEntities":{"people":[{"name":"Ryan Saadi","role":"Founder and CEO"}],"products":["Tevogen Bio","Tevogen.AI","ExacTcell"],"companies":[{"name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","relationship":"filer"},{"name":"Microsoft","relationship":"technology partner"},{"name":"Databricks","relationship":"technology partner"}],"dollarAmounts":[{"amount":"$100 million","context":"potential combined annual revenue from proposed acquisitions"}]},"materialImpact":{"score":3,"reasoning":"The company is actively pursuing acquisitions that could generate ~$100M in annual revenue, signaling a strategic pivot toward financial self-sufficiency. However, no definitive agreements are signed, and the transactions remain subject to due diligence and closing conditions, limiting immediate material impact."},"tickerRelevance":{"others":[{"ticker":"MSFT","relevance":"technology partner"},{"ticker":"DBK","relevance":"technology partner"}],"primary":"TVGN"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["operations_update"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"strategic-pivot","sectorWeight":"high","householdBrandBoost":"none","marketCapAdjustment":"low","retailFavoriteBoost":"low"}},"event_type":"m_and_a","event_type_secondary":["operations_update"],"sentiment":"bullish","material_impact_score":3,"narrative":"Tevogen is advancing strategic acquisition initiatives, including the evaluation of a contract research organization (CRO), aimed at building a financially self-sufficient healthcare enterprise.\n\nIf consummated, these transactions could support approximately $100 million in combined annual revenue, diversifying the company beyond its current biotechnology and AI arms.\n\nThe company emphasized capital discipline, noting that any acquisitions will be guided by strategic fit and long-term value creation, though no definitive agreements have been executed.","key_figures":{"customDimensions":{"potential_annual_revenue":"$100 million"}},"named_entities":{"people":[{"name":"Ryan Saadi","role":"Founder and CEO"}],"products":["Tevogen Bio","Tevogen.AI","ExacTcell"],"companies":[{"name":"Tevogen Bio Holdings Inc.","ticker":"TVGN","relationship":"filer"},{"name":"Microsoft","relationship":"technology partner"},{"name":"Databricks","relationship":"technology partner"}],"dollarAmounts":[{"amount":"$100 million","context":"potential combined annual revenue from proposed acquisitions"}]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-05-28T16:30:35.840Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"strategic-pivot","sectorWeight":"high","householdBrandBoost":"none","marketCapAdjustment":"low","retailFavoriteBoost":"low"}},"durationMs":35516,"modelName":"george-droid-qwen-72b"}}